Search

Search Constraints

You searched for: Author/Creator Rea, Daniel

Search Results

1. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Issue 10191 (29th June 2019)

2. Pathway-based subnetworks enable cross-disease biomarker discovery. Issue 1 (December 2018)

6. The nature of our mistakes, from promise to practice: Water stewardship for sustainable hydropower in Sub‐Saharan Africa. (31st August 2021)

7. The CD151‐midkine pathway regulates the immune microenvironment in inflammatory breast cancer. Issue 1 (24th March 2020)

9. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial. Issue 9 (September 2017)

10. Elderly Postmenopausal Patients With Breast Cancer Are at Increased Risk for Distant Recurrence: A Tamoxifen Exemestane Adjuvant Multinational Study Analysis. (20th December 2012)